Defining the causal effects of specific CpG methylation events has remained challenging due to the lack of methods for targeted conversion of 5mC to unmethylated cytosine in living cells. Currently, only nonspecific approaches exist for removing methyl groups from CpGs. For example, the cytidine analog 5-aza-2´-deoxycytidine (decitabine), an inhibitor of DNA methyltransferases, has been widely used to study the effects of demethylation on specific gene promoters. However, decitabine leads to global demethylation of CpGs in cells, making it difficult to use this reagent to establish causal effects. We sought in this work to demethylate CpGs in a targeted fashion at endogenous loci by fusing the hydroxylase activity of the human TET1 protein to engineered TALE repeat arrays with programmable DNA-binding specificities. Customized TALE repeat arrays make an attractive platform for directing TET1 activity because monomeric proteins that bind to nearly any target DNA sequence of interest can be robustly made by simple and rapid assembly of individual repeat domains with known single-base specificities 14 .
l e t t e r s
Defining the causal effects of specific CpG methylation events has remained challenging due to the lack of methods for targeted conversion of 5mC to unmethylated cytosine in living cells. Currently, only nonspecific approaches exist for removing methyl groups from CpGs. For example, the cytidine analog 5-aza-2´-deoxycytidine (decitabine), an inhibitor of DNA methyltransferases, has been widely used to study the effects of demethylation on specific gene promoters. However, decitabine leads to global demethylation of CpGs in cells, making it difficult to use this reagent to establish causal effects. We sought in this work to demethylate CpGs in a targeted fashion at endogenous loci by fusing the hydroxylase activity of the human TET1 protein to engineered TALE repeat arrays with programmable DNA-binding specificities. Customized TALE repeat arrays make an attractive platform for directing TET1 activity because monomeric proteins that bind to nearly any target DNA sequence of interest can be robustly made by simple and rapid assembly of individual repeat domains with known single-base specificities 14 .
In initial experiments, we defined the architecture of a TALE-TET1 fusion protein that could mediate efficient targeted conversion of 5mC to 5hmC at specific CpGs with resulting subsequent demethylation in human cells. To do this, we fused two TALE repeat arrays (KL-1 and KL-2), each engineered to bind a different site in the human KLF4 gene, with either full-length human TET1 or its catalytic domain (Fig. 1a,b and Online Methods). We then tested whether these four proteins could demethylate CpGs adjacent to the TALE binding sites (Fig. 1c) in human K562 cells using a bisulfite sequencing protocol that employs high-throughput next-generation sequencing to generate more than 10,000 sequencing reads per sample and which we validated using traditional Sanger sequencing (Online Methods, Supplementary Fig. 1 and Supplementary Table 1 ). For both KLF4 target sites, we found that TALE fusions bearing the TET1 catalytic domain induced significantly Genome-wide studies have defined cell type-specific patterns of DNA methylation 1 that are important for regulating gene expression in both normal development 2 and disease 3 . However, determining the functional significance of specific methylation events remains challenging, owing to the lack of methods for removing such modifications in a targeted manner. Here we describe an approach for efficient targeted demethylation of specific CpGs in human cells using fusions of engineered transcription activator-like effector (TALE) repeat arrays and the TET1 hydroxylase catalytic domain. Using these TALE-TET1 fusions, we demonstrate that modification of critical methylated promoter CpG positions can lead to substantial increases in the expression of endogenous human genes. Our results delineate a strategy for understanding the functional significance of specific CpG methylation marks in the context of endogenous gene loci and validate programmable DNA demethylation reagents with potential utility for research and therapeutic applications.
Methylation of DNA at cytosine bases is an important mechanism widely used to regulate gene expression and transposable elements in higher eukaryotic organisms 4 . Regions of hypermethylated DNA in mammalian cells are often associated with silenced, inactive chromatin, whereas regions of hypomethylated DNA are often associated with expressed genes and open chromatin 1,5 . In mammalian cells, the generation of methylated cytosine (5mC) is catalyzed and maintained by DNA methyltransferases primarily at CpG dinucleotides 6 . One pathway of active 5mC demethylation is initiated by the ten-eleven translocation (TET) family of proteins, enzymes that catalyze the oxidation of 5mC to 5-hydroxymethylcytosine (5hmC), a critical step that is thought to be important for ultimate removal of the methyl mark [7] [8] [9] [10] [11] [12] [13] . l e t t e r s We next determined whether TALE-TET1-induced demethylation of CpGs in human promoters might induce expression changes in proximal endogenous genes. The RHOXF2/2B homeobox gene (RHOXF2) is expressed primarily in male germ cells 15 . Plasmid-based reporter gene studies using decitabine have demonstrated that RHOXF2 expression in non-germ cells is strongly repressed by DNA methylation (M.E.R. et al., unpublished data). We engineered 11 TALE-TET1 proteins (RH-1 through RH-11) targeted to sites that lie in close proximity to a total of 18 different CpGs in the RHOXF2 promoter ( Fig. 2a and Supplementary  Table 2 ). We transfected both HEK293 and HeLa cells with plasmids encoding each of these 11 TALE-TET1 proteins, and then measured RHOXF2 expression and promoter methylation status using quantitative RT-PCR and high-throughput bisulfite sequencing ( Supplementary  Fig. 5 ). The RH-3 fusion was expected to bind both targeted regions of the RHOXF2 promoter; however, demethylation of CpGs in the -650 to -850 region were observed only in HEK293 cells because cytosines in this region are not methylated in HeLa cells (Supplementary Figs. 5 and 6 and data not shown).
Three out of the six fusions targeting the region most proximal to the transcriptional start site (-250 to +1) induced significant (P < 0.05) demethylation >15% in both HeLa and HEK293 cells ( Supplementary  Fig. 5 ). Among the six constructs targeting the -650 to -850 region, three induced significant (P < 0.05) demethylation >15% in HEK293 cells ( Supplementary Fig. 5 ). Two of the constructs that demethylated CpGs in the region most proximal to the RHOXF2 promoter (RH-3 and RH-4) induced high levels of mRNA expression in both the HEK293 and HeLa cell lines (Fig. 2b,c) . Presumably, fusions that demethylate CpGs but do not increase RHOXF2 expression are not affecting CpGs critical for expression from the promoter. We found that even greater increases in RHOXF2 expression could be induced by combined expression of both the RH-3 and RH-4 proteins in HEK293 cells (Supplementary Fig. 7) . Understanding the mechanism for this increased expression will be a focus of future studies.
To assess whether the enzymatic activity of the TET1 domain is important for the gene activation observed with the RH-3 and RH-4 proteins, we tested variant fusions bearing mutations (H1671Y, D1673A) known to inactivate TET1 catalytic activity 7 . We found that these (P < 0.05) greater decreases in methylation of CpGs proximal to the TALE binding site than those bearing the full-length TET1 protein ( Fig. 1d,e ). For example, one of the TALE-TET1 catalytic domain fusion proteins reduced the methylation of CpGs located 10 and 16 bp from the 3´ boundary of the TALE binding site by 21% and 30%, respectively, with similar levels of demethylation observed on both DNA strands ( Supplementary Fig. 2 ). Lengthening the linker between the TALE repeat array and the TET1 catalytic domain did not appreciably alter demethylation efficiencies observed ( Supplementary Fig. 3 ). Therefore, all subsequent experiments used TALE-TET1 catalytic domain proteins with a short Gly-Gly-Gly-Ser linker (hereafter referred to as simply "TALE-TET1" fusion proteins). Control fusion proteins bearing a TALE repeat array targeted to an unrelated EGFP reporter gene sequence did not demethylate CpGs in the KLF4 intron ( Fig. 1d,e ), demonstrating that demethylation requires specific binding to the target locus by the TALE repeats and is not due simply to overexpression of proteins harboring TET1 hydroxylase activity. Based on a dose-response experiment, which showed increased levels of demethylation in cells transfected with greater amounts of plasmid encoding a TALE-TET1 protein, we identified optimal transfection conditions that maximized both CpG demethylation and cell viability ( Supplementary  Fig. 4) . l e t t e r s increases in HBB gene expression as measured by quantitative RT-PCR were observed with only four of these proteins (HB-3, HB-4, HB-5 and HB-6) ( Fig. 3d) . Of note, the three proteins (HB-4, HB-5 and HB-6) that induced the greatest fold-activation of the promoter were the fusions that induced the greatest demethylation of the CpG at position -266 (numbered relative to the transcription start site; Fig. 3d ). HB-4, HB-5 and HB-6 proteins bearing an inactive TET1 catalytic domain did not demethylate the -266 CpG and also did not efficiently activate HBB gene expression in K562 cells ( Fig. 3e,f) . Western blot analysis confirmed that the loss of demethylation and gene activation activities observed with the catalytically inactive mutants of HB-5 and HB-6 is not due to decreased protein expression in K562 cells ( Supplementary Fig. 9 ). Furthermore, time-course experiments showed that both demethylation of the -266 CpG and activated expression of HBB diminish as transfected cells continue to be cultured (Supplementary Results and Supplementary  Fig. 10 ), suggesting that continued expression of TALE-TET1 is required to maintain these effects. Taken together, our findings suggest that either hydroxylation and/or demethylation of this particular methylated CpG is required for the observed activation of HBB expression. We have described an approach for targeting 5-methylcytosine hydroxylase activity with subsequent cytosine demethylation to any catalytically inactive RH-3 and RH-4 mutants neither demethylated their proximal CpGs nor activated RHOXF2 gene expression in HEK293 or HeLa cells ( Fig. 2b,c,e ). Western blot analysis confirmed that the observed inactivity of these RH-3 and RH-4 mutant proteins is not due to their decreased expression in HEK293 cells (Supplementary Fig. 8) .
These results suggest that activation of RHOXF2 expression is mediated by TALE-TET1-induced modification (either hydroxylation and/ or demethylation) of specific methylated CpGs in the promoter and not simply by competitive binding of TALE-TET1 fusions with endogenous transcription factors or the presence of a fortuitous transcriptional activation function within the fusion protein.
To further generalize these results, we next sought to demethylate CpGs in an additional locus, the human beta-globin (HBB) gene promoter. Previous work has suggested that four CpGs, which are differentially methylated in erythroid cells isolated from fetal liver and adult bone marrow, may play a role in regulating HBB expression 16 . To test this hypothesis, we constructed ten TALE-TET1 proteins targeted to various sites proximal to these four CpGs ( Fig. 3a and Supplementary Table 2 ). Although all ten TALE-TET1 fusions (termed HB-1 through HB-10) induced significant (P < 0.05) demethylation of CpGs near their respective binding sites in human K562 cells (Fig. 3b,c ), significant (P < 0.05) npg l e t t e r s demethylation within 30 bp of either end of the TALE target binding site, some fusions also induced demethylation of CpGs ~150-200 bp away from the target site, suggesting that the TET1 catalytic domain might also access regions of open chromatin located at least one nucleosome distance away. In this study, we only examined CpGs proximal to the TALE-TET1 binding site, but it is possible that other sites elsewhere in the genome might also be modified because of higher-order interactions in the three-dimensional structure of nuclear DNA. Our success rate for making TALE-TET1 fusions capable of modifying methylated cytosines was high but varied by target gene. For KLF4 and HBB, all 12 fusions we made (two at KLF4 and ten at HBB) induced demethylation >15% at CpGs adjacent to their target binding sites; however, for the RHOXF2 promoter, only ~50% of the fusions we made induced demethylation >15% in both HeLa and HEK293 cells. The inability of some fusions to mediate substantial demethylation might endogenous genomic locus of interest in living cells. Whereas the majority of cytosines that are converted to uracil in our bisulfite experiments are most likely to be unmethylated cytosines, it is possible that a very small percentage of these might also represent 5-formylcytosine (5fC) or 5-carboxylcytosine (5caC), further oxidation products of 5hmC catalyzed by TET1 (ref. 9). However, given that 5fC and 5caC are rapidly removed from DNA by thymine DNA glycosylase-mediated excision 17 , these oxidation products are most likely short-lived in these cells. Therefore, we presume that these species will be present at very low levels, as has been previously observed in other mammalian cells 9 .
The TALE-TET1 framework can be easily programmed to target essentially any DNA sequence using the simple TALE repeat code, and we used this platform to induce locus-specific demethylation at three endogenous genes (KLF4, RHOXF2 and HBB) in three different human cell lines. Although we frequently observed the greatest degree of npg l e t t e r s depend upon the TALE repeat array-mediated sequence-specific localization of TET1 activity. We also do not yet understand why some CpGs are more efficiently demethylated than others by our TALE-TET1 fusions. For example, we were able to demethylate some CpGs in the HBB locus very efficiently (as high as 84%), whereas other CpGs in the RHOXF2 locus were less efficiently demethylated (maximum of 42% and 25% in HeLa and HEK293 cells, respectively). As noted above, this could be partly due to locusspecific effects that influence the DNA-binding and/or hydroxylase activities of the fusions. However, it is also possible that various factors in the cells may be actively re-methylating CpGs and thus the extent of methylation observed may represent a steady-state between de-and remethylation. Our time-course results at the HBB locus ( Supplementary  Fig. 10) are consistent with the idea that re-methylation may be occurring in K562 cells because demethylated CpGs appear to become remethylated as the TALE-TET1-encoding plasmid is lost from the cells.
The TALE-TET1 platform described here and other fusion proteins recently described by our group 20 and others 21 represent potentially useful additions to the growing toolbox of reagents for performing targeted editing of epigenomic modifications. Previously described reagents that target histone methyltransferases (SUV39H1 and G9A 22 ) or DNA methyltransferases (bacterial enzymes [23] [24] [25] [26] [27] and human DNA methyltransferase 3a and 3b subunits [28] [29] [30] ) used engineered zinc finger proteins, which can be more challenging to construct than TALEs. Continued construction and characterization of tools to modify histones and DNA methylation might in the future enable stable, heritable changes in the expression of any gene of interest. Development of such a capability would enable numerous research applications as well as potential therapeutic strategies for diseases caused by dysregulated gene expression.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. All raw sequenced reads and BSMAP processed data files, GEO: GSE50761. be caused by locus-dependent effects that influence target site occupancy such as chromatin structure, nucleosome occupancy, DNA methylation or other parameters that could have an impact on DNA-binding by the TALE repeat arrays and/or the efficiency of hydroxylation by the TET1 catalytic domain.
Our experiments provide a framework for using TALE-TET1 proteins to evaluate the functional significance of specific CpG (and possibly non-CpG cytosine) methylation events. In this report, we successfully identified several CpGs within the RHOXF2 promoter and a single CpG within the HBB promoter that, when modified by either hydroxylation and/or demethylation, are associated with an increase in gene expression. Even modest levels of methylated CpG modification in the population of cells can, in some cases, be associated with high levels of gene activation. Although the particular CpGs we identified in our transformed cancer cell-based experiments may or may not be involved in normal physiologic regulation of the RHOXF2 or HBB genes, our experiments nonetheless illustrate a general strategy that could be used in other more physiologically relevant cell types (e.g., primordial germ or erythroid cells) to define critical methylation events involved in the regulation of these genes. Additionally, our TALE-TET1 fusions should provide important tools for performing other, more detailed mechanistic studies that define how the loss of methylation marks in turn leads to increases in promoter activity (e.g., by enhancing or reducing the binding of particular transcription factors).
An important and as-yet unanswered issue for future studies will be to define the genome-wide specificities of our TALE-TET1 proteins. All of the proteins we constructed for the RHOXF2 and HBB promoters were designed to bind 20-bp sites, sequences sufficiently long to be potentially unique in the human genome. However, although previously published in vitro SELEX experiments suggest that monomeric TALE repeat arrays are specific for their intended target sites 18 , to our knowledge the genome-wide specificities of such proteins in human cells have not been described. Engineered zinc finger (ZF) proteins might provide a potential alternative to TALE repeat arrays for targeting TET1 activity and at least one published report has suggested that monomeric six-finger proteins can be highly specific in human cells 19 . We have also engineered multiple six-finger ZF-TET1 fusion proteins targeted to 18-bp sequences in the KLF4 and HBB genes (Online Methods) and demonstrated that these can induce targeted demethylation with efficiencies comparable to those induced by TALE-TET1 proteins (Supplementary Results  and Supplementary Figs. 11 and 12) . Regardless of which platform ultimately proves to be more specific, potential off-target effects can be readily accounted for by constructing and testing multiple targeted TALE-TET1 or ZF-TET1 fusion proteins for each CpG or cluster of CpGs to be demethylated. For example, our finding that three different TALE-TET1 proteins can all demethylate a common CpG and induce changes in HBB gene expression strongly suggests that the observed phenotype is due to binding at the intended target sequence and not at an off-target site elsewhere in the genome.
In addition to off-target effects resulting from unintended binding elsewhere in the genome, it is also possible that TALE-TET1 fusions could induce demethylation that is not dependent upon binding by the TALE repeat array portion of the protein. This can be seen in some of our experiments with fusions targeted to an off-target site in the KLF4 gene causing some nonspecific demethylation at the HBB locus (Fig. 3b,c) , presumably caused by non-DNA-bound proteins acting from solution. Until such nonspecific effects can be minimized (perhaps by decreasing or controlling the expression level of TALE-TET1 proteins), these results highlight the need to always perform controls with fusions targeted to other off-target sites. These controls will be crucial for interpreting whether phenotypic effects induced by a particular TALE-TET1 protein npg l e t t e r s qRT-PCR assays. For assay of HBB gene expression, RNA was reverse transcribed using the SuperScript III First-Strand Synthesis SuperMix and oligo-dT (Life Technologies). Quantitative PCR was performed with Taqman Universal PCR Mastermix (Applied Biosystems) on an ABI 7500 Fast Real-Time PCR system with the following primer/probe sets: Forward HBB primer 5´-CAAGGGCACCTTTGCCACAC-3´; Reverse HBB Primer 5´-TTTGCCAAAGTGATGGGCCA-3´; HBB Taqman Probe 5´-/56-FAM/ CCTGGGCAA/ZEN/CGTGCTGGTCTGTGT/3IABkFQ/-3´; Forward b-actin (ACTB) Primer: 5´-GGCACCCAGCACAATGAAG-3´; Reverse ACTB primer 5´-GCCGATCCACACGGAGTACT-3´; ACTB Taqman Probe 5´-/5MAX550-Y/ TCAAGATCA/ZEN/TTGCTCCTCCTGAGCGC/3IABlk_FQ/-3´.
For assay of RHOXF2 gene expression, RNA was reverse transcribed using iScript cDNA Synthesis Kit (BioRad) according to manufacturer's protocol. qPCR was done with SsoAdvanced SYBRGreen Supermix (BioRad) on an ABI StepOnePlus instrument with the following primers: RHOXF2 Forward primer 5´-GGCAAGAAGCATGAATGTGA-3´; RHOXF2 Reverse primer 5´-TGTCTCCTCCATTTGGCTCT-3´; M/H Actin Forward primer 5´-GTCCACACCCRCCGCCAG-3´; M/HActin Reverse primer 5´-CCCACGATGGAGGGGAA-3´. Note that this assay does not distinguish between RHOXF2 and RHOXF2B.
All transfections were done in triplicate and for each biological replicate at least three technical replicates of the qPCR assay were done. Statistical significance was determined by comparing experimental samples against the off-target control using a one-sided t-test after confirming that data sets exhibited a normal distribution as determined by a Shapiro-Wilk test for normality (P < 0.05). The similarity of variance between groups was determined using an f-test. When variance was equal between data sets, a two-sample equal variance t-test was used and when variance was unequal, a Welch's t-test was used.
ZF-TET1 fusion protein design and construction.
Six-finger zinc finger arrays were assembled using two-finger units derived from three-finger proteins selected by the OPEN method 32 . Assembled six-finger proteins were fused to the catalytic domain of TET1 using the linker sequence Leu-Arg-Gly-Ser and to an N-terminal nuclear localization signal with expression of the ZF-TET1 fusion protein driven by an EF1a promoter.
Western blot analysis. Transfected cells were lysed in radioimmunoprecipitation assay protein extraction buffer (Cell Signaling) and centrifuged for 5 min at 4 °C to harvest the supernatant. The concentration of the extracted protein was determined using a Thermo Scientific protein assay kit. Ten micrograms of the extracted protein were loaded per lane onto 4% to 12% Tris-glycine gels (Life Technologies) for electrophoresis, and electro-transferred to nitrocellulose membrane (Life Technologies). This membrane was blocked with 5% nonfat dry milk in Tris-buffered Saline-Tween buffer (25 mM Tris (pH 7.4), 137 mM NaCl, 2.7 mM KCl, 0.1% Tween 20) for 1 h at room temperature, followed by incubation with monoclonal Anti-FLAG M2 antibody (Sigma, F3165, 1:7,500 dilution) and b-actin (C4) HRP monoclonal antibody (Santa Cruz Biotechnology, sc-47778, 1:40,000 dilution) in blocking buffer for 2 h at room temperature. After washing with TBS-T buffer, the membrane was incubated with goat anti-mouse IgG (H+L)-HRP conjugate antibody (Bio-Rad Laboratories, 172-1011, 1:10,000 dilution) in blocking buffer for 1 h at room temperature. The membrane was developed using ImmunoCruz chemiluminescence system (Santa Cruz Biotechnology) and exposed to BioMax XAR film (Kodak).
Additional experimental details for bisulfite PCR. All PCR primer sequences are provided in Supplementary Table 1 . Standard Illumina multiplex adapters and indexes were added by PCR for both KLF4 amplicons and for HBB amplicon #3, and standard Illumina multiplex adapters were ligated to RHOX bisulfite PCR amplicons and to HBB PCR amplicons #1 and #2, and indexes were added by PCR, as described below. 
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ONLiNE METHODS
TALE-TET1 fusion protein design and construction.
The full TET1 coding sequence was synthesized in segments (Integrated DNA Technologies) and assembled by standard restriction enzyme digest and ligation to construct TET1-FL and TET1-catalytic domain (CD) expression vectors. All TALEs were assembled using the FLASH method and were cloned into TALE-TET1 expression vectors (pJA344C7, pJA345D4, pJA344E9 and pJA247) containing one of four 0.5 C-terminal TALE repeats, an N-terminal nuclear localization signal, the Δ152 TALE N-terminal domain and the +95 TALE C-terminal domain, as previously described 18, 31 . In all expression plasmids used, either TET1-FL or TET1-CD was fused to the C-terminal end of the TALE-derived DNA-binding domain by means of a Gly-Gly-Gly-Ser linker and expression of this fusion was driven by an EF1alpha promoter. For the western blot analysis experiments, expression vectors had an additional triple-FLAG tag cloned upstream of the nuclear localization signal. Sequences of all constructs are shown in Supplementary Figure 13 .
Cell culture and transfection. FlpIn-TRex HEK293 (Life Technologies) and HeLa (American Type Culture Collection, ATCC) cells were cultured in advanced DMEM supplemented with 10% FBS, 1% glutamax and 1% penicillinstreptomycin (Invitrogen). K562 (ATCC) cells were maintained in RPMI supplemented with 10% FBS, 1% glutamax and 1% penicillin-streptomycin. All cell lines were tested for mycoplasma every 2 weeks. Plasmids encoding TALE-TET1 fusions targeted to the KLF4 and HBB loci were transfected into K562 cells by Nucleofector technology (Lonza). Briefly, 10 μg of TALE-TET1-encoding plasmid (or 2, 5, 10, 20 or 50 μg in the dose-response experiment) and 500 ng pmaxGFP plasmid were nucleofected into 1 × 10 6 K562 cells using Kit V (Lonza) and program T-016. Control transfections used 500 ng pmaxGFP plasmid (Lonza). Fluorescent microscopy was used to ensure consistent and high levels of transfection efficiency in all K562 experiments and FACS analysis showed ~80-90% of transfected cells are GFP + under these conditions. HeLa and HEK293 cells were transfected with plasmids encoding TALE-TET1 fusions targeted to human RHOXF2 using Lipofectamine LTX according to the manufacturer's instructions (Life Technologies). Briefly, 3.2 × 10 5 HEK293 cells or 1 × 10 5 HeLa cells were seeded into 12-well plates and transfected the following day with 1.2 µg TALE-TET1-encoding plasmid, 60 ng pmaxGFP plasmid, 1 µl Plus reagent and 3.3 µl Lipofectamine LTX. Fluorescent microscopy was used to ensure consistent and high levels of transfection efficiency. Cell viability in K562 cells was assayed by resuspending cells in PBS with 10% FBS and 1 mg/ml propidium iodide and analyzing by fluorescence-activated cell sorting (FACS).
Genomic DNA and total RNA isolation. Four days post-transfection, genomic DNA (gDNA) was isolated using the QIAamp DNA Blood Mini Kit (Qiagen) according to manufacturer's protocol. Total RNA was isolated from cells transfected with plasmids encoding TALE-TET1 fusions targeting HBB or RHOXF2 using the PureLink RNA Mini Kit (Ambion) according to the manufacturer's instructions. RNA was treated with TurboDNA-Free (Ambion).
High-throughput bisulfite sequencing. 500 ng of genomic DNA isolated from transfected cells was bisulfite treated using the EZ DNA methylation, EZ DNA Methylation-Gold or EZ DNA Methylation-Lightning Kit (Zymo Research) according to the manufacturer's instructions. All samples underwent bisulfite conversion with an efficiency of at least 98.5% as judged by conversion of unmethylated, non-CpG cytosines. Genomic DNA sites in KLF4, HBB and RHOXF2 were amplified by PCR using bisulfite-converted gDNA as a template with Kapa HiFi HotStart Uracil+ ReadyMix (Kapa Biosystems) (for KLF4 and HBB sites) or Qiagen's PyroMark PCR Kit (for RHOXF2 sites). Standard Illumina adaptors were added by either ligation or PCR and Illumina multiplex barcodes were added by PCR. For details of PCR reactions, see below. Pooled amplicons were sequenced using an Illumina MiSeq with 150 bp paired-end reads (Dana-Farber Molecular Biology Core Facilities Genomics Core). For each experimental sample assayed, we analyzed between 10,000 and 375,000 reads. Note that because RHOXF2 and RHOXF2B sequences are identical in the region examined, the bisulfite PCR analysis does not distinguish between these two loci. For confirmatory Sanger sequencing of KLF4 samples, initial bisulfite PCR products were cloned using the TOPO Zero-Blunt cloning kit (Life Technologies) and used to transform Escherichia coli. Plasmid DNA was purified from the resulting colonies and sequenced by the Massachusetts General Hospital DNA Core facility. 
